Stock comparison
Aktis Oncology
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AKTS
Aktis Oncology
Market cap
$1.09B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AKTS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 55D | 75B | IDXX |
| Benjamin Graham | 46D | 80A | IDXX |
| Philip Fisher | 82C | 75B | AKTS |
| Peter Lynch | 5F | 71B | IDXX |
| Joel Greenblatt | 4F | 83C | IDXX |
| Charlie Munger | 82D | 87A | IDXX |
| Terry Smith | 88C | 84A | AKTS |
Side-by-side metrics
| Metric | AKTS | IDXX |
|---|---|---|
| Market cap | $1.09B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | -10.12% | 40.66% |
| Gross margin | 89.19% | 62.05% |
| Net margin | -7.55% | 24.63% |
| Revenue CAGR 5y | - | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AKTS leads on
- P/E (TTM)-vs 39.0x+161%
- EV/EBIT-vs 31.6x+129%
- Debt / Equity0.0xvs 0.7x+97%
- Gross margin89.19%vs 62.05%+30%
IDXX leads on
- ROIC (TTM)40.66%vs -10.12%+125%
- Net margin24.63%vs -7.55%+103%
- Market cap$44.12Bvs $1.09B+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.